FIELD: medicine.
SUBSTANCE: invention relates to the hCoV-19/Russia/Omsk-202118-1707/2020 strain of the SARS-CoV-2 virus, an immunosorbent containing a whole virion antigen obtained using said strain, and an ELISA test system for detecting antibodies of classes M, G and A to the SARS-CoV-2 coronavirus and can be used in medical virology. The specified technical result is achieved by obtaining the hCoV-19/Russia/Omsk-202118-1707/2020 strain of the SARS-CoV-2 virus deposited in the State collection of viral pathogens and rickettsioses of the FBSI SSC VB Vector of Rospotrebnadzor. The specified technical result is also achieved by obtaining an immunosorbent containing the whole virion antigen of the SARS-CoV-2 virus, used as a component of an enzyme-linked immunosorbent assay for detecting antibodies of classes M, G and A to the SARS-CoV-2 virus. The specified technical result is also achieved by the manufacture of an enzyme-linked immunosorbent assay for detecting antibodies of classes M, G and A to the SARS-CoV-2 virus containing the above immunosorbent.
EFFECT: invention increases the sensitivity of a set of reagents for a two-stage solid-phase indirect enzyme-linked immunosorbent assay (ISA) using a whole virion antigen obtained on the basis of the claimed hCoV-19/Russia/Omsk-202118-1707/2020 strain of the SARS-CoV-2 virus.
4 cl, 11 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TEST SYSTEM AND METHOD FOR DIFFERENTIAL DETECTION OF ANTIBODIES TO SARS-COV-2 | 2021 |
|
RU2754340C1 |
| METHOD FOR DETERMINING THE SPECIFIC CELLULAR IMMUNE RESPONSE TO CORONAVIRUS ANTIGENS (SARS-CoV-2) | 2021 |
|
RU2780369C1 |
| METHOD FOR ENZYME IMMUNOASSAY DETERMINATION OF THE LEVEL OF ANTIGEN-RECOGNIZING B-LYMPHOCYTE RECEPTORS REPRESENTED BY MEMBRANE-SPECIFIC RBD PROTEIN SARS-COV-2, IgG ANTIBODIES | 2021 |
|
RU2760438C1 |
| METHOD FOR CARRYING OUT AN ENZYME-LINKED IMMUNOSORBENT ASSAY FOR THE DETECTION OF ANTIBODIES IN A HUMAN BIOLOGICAL SAMPLE SPECIFIC TO THE SARS-COV2 HUMAN CORONAVIRUS, A TEST SYSTEM | 2021 |
|
RU2759149C1 |
| METHOD OF USING RECOMBINANT PROTEINS SARS-COV-2 AS PART OF A TEST SYSTEM FOR ELISA TEST WITH DETERMINING IGM, IGG, IGA CLASS ANTIBODY LEVELS IN BLOOD SERUM/PLASMA OF COVID-19 PATIENTS | 2020 |
|
RU2730897C1 |
| METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 | 2021 |
|
RU2784655C1 |
| METHOD FOR DETECTING ANTIBODIES TO SARS-CoV-2 IN MIXED SALIVA | 2022 |
|
RU2787171C1 |
| METHOD FOR DETECTING INFECTION OF HUMANS AND ANIMALS WITH SARS CoV 2 AND A DIAGNOSTIC KIT FOR IMPLEMENTING THE METHOD | 2021 |
|
RU2776295C1 |
| Method for producing Chinese hamster ovary cell strain, being a producer of recombinant SARS-CoV-2 virus protein RBD, Chinese hamster ovary cell strain, producer of recombinant SARS-CoV-2 protein RBD, method for producing recombinant SARS-CoV-2 virus protein RBD, test system for enzyme immunoassay of human serum or plasma, and use thereof | 2020 |
|
RU2723008C1 |
| METHOD FOR DETERMINING AND QUANTIFYING SPECIFIC CELLULAR IMMUNITY TO SARS-CoV-2 VIRUS S-PROTEIN ANTIGENS | 2021 |
|
RU2762616C1 |
